Goodarzi Zahra, Mele Bria, Guo Selynne, Hanson Heather, Jette Nathalie, Patten Scott, Pringsheim Tamara, Holroyd-Leduc Jayna
Department of Community Health Sciences, University of Calgary, Calgary, Canada.
Department of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada.
BMC Neurol. 2016 Nov 25;16(1):244. doi: 10.1186/s12883-016-0754-5.
Depression and anxiety remain under-diagnosed and under-treated in those with neurologic diseases such as dementia or Parkinson's Disease (PD). Our objectives were to first, to provide a synthesis of high quality guidelines available for the identification and management of depression or anxiety in those with dementia or PD. Second, to identify areas for improvement for future guidelines.
We searched MEDLINE, PsycINFO, and EMBASE (2009 to July 24, 2015), grey literature (83 sources; July 24-Sept 6, 2015), and bibliographies of included studies. Included studies were evaluated for quality by four independent reviewers the AGREE II tool. Guideline characteristics, statements and recommendations relevant to depression or anxiety for dementia and PD were then extracted. (PROSPERO CRD: 42016014584) RESULTS: 8121 citations were reviewed with 31 full text articles included for assessment with the AGREE II tool. 17 were of sufficient quality for inclusion. Mean overall quality scores were between 4.25 to 6.5. Domain scores were lowest in the areas of stakeholder involvement, applicability, and editorial independence. Recommendations for the screening and diagnosis of depression were found for PD and dementia. There was little evidence to guide diagnosis or management of anxiety. Non-pharmacologic therapies were recommended for dementia patients. Most advocated pharmacologic treatment for depression, for both PD and dementia, but did not specify an agent due to lack of evidence.
The available recent high quality guidelines outline several recommendations for the management of comorbid depression or anxiety in PD or dementia. However there remain significant gaps in the evidence.
在患有痴呆症或帕金森病(PD)等神经系统疾病的人群中,抑郁症和焦虑症的诊断和治疗仍不足。我们的目标是,首先,综合高质量指南,以识别和管理痴呆症或帕金森病患者的抑郁症或焦虑症。其次,确定未来指南有待改进的领域。
我们检索了MEDLINE、PsycINFO和EMBASE(2009年至2015年7月24日)、灰色文献(83个来源;2015年7月24日至9月6日)以及纳入研究的参考文献。由四名独立评审员使用AGREE II工具对纳入研究的质量进行评估。然后提取与痴呆症和帕金森病的抑郁症或焦虑症相关的指南特征、声明和建议。(国际前瞻性系统评价注册库编号:42016014584)结果:共检索到8121条引文,其中31篇全文文章纳入评估并使用AGREE II工具。17篇质量足够可纳入。平均总体质量得分在4.25至6.5之间。在利益相关者参与、适用性和编辑独立性方面,领域得分最低。发现了针对帕金森病和痴呆症患者抑郁症筛查和诊断的建议。几乎没有证据可指导焦虑症的诊断或管理。推荐对痴呆症患者采用非药物疗法。大多数人主张对帕金森病和痴呆症患者的抑郁症进行药物治疗,但由于缺乏证据未指定具体药物。
现有的近期高质量指南概述了一些关于帕金森病或痴呆症合并抑郁症或焦虑症管理的建议。然而,证据方面仍存在重大差距。